Evidence mapPaperPMID 30343339Full record

ReviewCurrent diabetes reports2018

Revisiting the Diabetes-Heart Failure Connection.

Markus Wallner, Deborah M Eaton, Dirk von Lewinski, Harald Sourij

Abstract readReview
In one paragraph

Review in Current diabetes reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Markus WallnerDivision of Cardiology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Deborah M EatonCardiovascular Research Center, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA.
Dirk von LewinskiDivision of Cardiology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Harald SourijCenter for Biomarker Research in Medicine, CBmed, Graz, Austria. ha.sourij@medunigraz.at.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of the reviewTo summarize current clinical data investigating the link between diabetes and heart failure pathophysiology, the association of glucose control with heart failure, and the impact of current antihyperglycemic drugs on heart failure. RECENT

findingsAlthough heart failure is one of the most prevalent outcomes occurring in real life and cardiovascular outcome trials, insufficient attention was given to this condition in diabetes research over the last decades. With both beneficial and detrimental findings for heart failure hospitalization in the health authority-mandated outcome trials for new antihyperglycemic agents, research on heart failure and its interplay with diabetes mellitus gained momentum. Diabetes mellitus and heart failure are both prevalent and intertwined conditions. While currently available heart failure therapies have a similar degree of effectiveness in patients with and without diabetes, the choice of glucose-lowering agents can substantially affect heart failure-related outcome.

Indexed as

Clinical Trials as TopicDiabetes Mellitus, Type 2Heart FailureHumansHypoglycemic AgentsHypoglycemic AgentsAntihyperglycemic drugDiabetesHeart failureIncretin-based therapyPathogenesisSGLT-2 inhibitorsTreatment

Identifiers

PMID30343339
PMCPMC6209037

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.